{"id":"c21","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL5789168","moleculeType":null,"molecularWeight":"504.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CD40 is a co-stimulatory molecule on antigen-presenting cells and B cells. Agonism of CD40 promotes T-cell activation, B-cell maturation, and dendritic cell function, leading to enhanced adaptive immunity against cancer. This mechanism is being explored in combination with checkpoint inhibitors and other immunotherapies.","oneSentence":"C21 is a CD40 agonist that activates the CD40 receptor on immune cells to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:57.606Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT06588686","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.","status":"RECRUITING","sponsor":"Vicore Pharma AB","startDate":"2024-12-09","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":360},{"nctId":"NCT06977724","phase":"PHASE1","title":"A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-08-26","conditions":"Dry Eye Syndrome, Systemic Lupus Erythematosus","enrollment":36},{"nctId":"NCT03899792","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-06-13","conditions":"Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma","enrollment":36},{"nctId":"NCT03738592","phase":"NA","title":"Spatial Hearing Perception in Bilateral Cochlear Implant Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-01-24","conditions":"Cochlear Impant Children","enrollment":36},{"nctId":"NCT03157128","phase":"PHASE1, PHASE2","title":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2017-05-02","conditions":"Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer","enrollment":857},{"nctId":"NCT05937841","phase":"EARLY_PHASE1","title":"Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-06-28","conditions":"Preeclampsia Postpartum","enrollment":30},{"nctId":"NCT03037385","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-17","conditions":"RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer","enrollment":590},{"nctId":"NCT04533022","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2020-11-13","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":52},{"nctId":"NCT05277922","phase":"PHASE1","title":"Effect of C21 on Forearm Blood Flow","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2022-04-28","conditions":"Study Vasodilatory Effects of C21","enrollment":5},{"nctId":"NCT05830799","phase":"PHASE1","title":"A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2023-03-29","conditions":"Drug Interaction","enrollment":19},{"nctId":"NCT05576155","phase":"EARLY_PHASE1","title":"Sex Differences in the Dilatory Response of Compound 21","status":"COMPLETED","sponsor":"Anna Stanhewicz, PhD","startDate":"2022-10-03","conditions":"Sex Differences","enrollment":26},{"nctId":"NCT06157580","phase":"EARLY_PHASE1","title":"Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia","status":"COMPLETED","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-12-08","conditions":"Preeclampsia","enrollment":24},{"nctId":"NCT05831644","phase":"PHASE1","title":"A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2023-03-31","conditions":"Type2diabetes, Endothelial Dysfunction","enrollment":11},{"nctId":"NCT04199078","phase":"NA","title":"Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.","status":"COMPLETED","sponsor":"Procare Health Iberia S.L.","startDate":"2019-09-25","conditions":"Human Papilloma Virus, Human Papilloma Virus Infection, Cervix Lesion","enrollment":288},{"nctId":"NCT06284122","phase":"PHASE3","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2024-06-07","conditions":"Follicular Lymphoma","enrollment":790},{"nctId":"NCT04878913","phase":"","title":"Retrospective Evaluation of Lung Pathology in Subjects With COVID-19","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2021-07-07","conditions":"COVID-19, COVID-19 Pneumonia","enrollment":35},{"nctId":"NCT05219513","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-02-18","conditions":"Lymphoma, Non-Hodgkin","enrollment":53},{"nctId":"NCT06508606","phase":"PHASE2","title":"AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-08-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":10},{"nctId":"NCT04880642","phase":"PHASE3","title":"A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2021-09-16","conditions":"COVID-19","enrollment":272},{"nctId":"NCT04388176","phase":"PHASE2","title":"Cold Challenge With C21 in RP","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2020-01-03","conditions":"Raynaud Phenomenon, Systemic Sclerosis","enrollment":20},{"nctId":"NCT04452435","phase":"PHASE2","title":"Safety and Efficacy of C21 in Subjects With COVID-19","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2020-07-21","conditions":"COVID-19","enrollment":206},{"nctId":"NCT03673215","phase":"EARLY_PHASE1","title":"The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment","status":"UNKNOWN","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2018-06-28","conditions":"Liver Cirrhosis","enrollment":58},{"nctId":"NCT00005639","phase":"PHASE1","title":"Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-03","conditions":"Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":34},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT00928213","phase":"PHASE2, PHASE3","title":"PP13 and Doppler Study to Predict Preeclampsia","status":"UNKNOWN","sponsor":"Ben-Gurion University of the Negev","startDate":"2009-08","conditions":"Preeclampsia","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Buloxibutid","Compound 21","Compund 21","Buloxibutid, Compound 21"],"phase":"phase_3","status":"active","brandName":"C21","genericName":"C21","companyName":"Vicore Pharma AB","companyId":"vicore-pharma-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"C21 is a CD40 agonist that activates the CD40 receptor on immune cells to enhance anti-tumor immune responses. Used for Advanced solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}